Binnopharm: Venarus (venotonizing and venoprotective drug)

Main article: Cardiovascular diseases

2023: Registration for commercial circulation in Azerbaijan

Binnopharm Group"" continues to develop a portfolio of drugs countries EEU in and. In CIS September 2023 Azerbaijan , a venotonizing and venoprotective drug in Venarus tablets at doses of 50 mg + 450 mg and 900 mg + 100 mg was registered for commercial circulation in. The company announced this on September 20, 2023.

As of September 2023, two OTS brands "Binnopharm Group" - Kagotsel and Neobutin - are already actively sold in pharmacies in Azerbaijan.

Thanks to the implementation of the expansion strategy of international expansion in 2023, Binnopharm Group is the leader in the number of clinical trials in Russia for registration, including in the EAEU and CIS countries. Seven Binnopharm Group drugs are undergoing clinical trials in September 2023. In the same year, six more clinical trials are planned.

Binnopharm Group is actively developing its product portfolio in the countries where it operates. First of all, we are trying to bring to foreign markets the most successful brands of Binnopharm Group, which include venotonic Venarus - drug No. 2 in our portfolio. I am sure that it will be successful in the Azerbaijani market, as it has a good reputation both among healthcare professionals and consumers, said Ekaterina Slavgorodskaya, director of sales and promotion at Binnopharm Group.